InflaRx presents pre-clinical izicopan data at Kidney Week 2026
The company reported that izicopan reduced kidney injury markers in two hamster models and described structural data distinguishing it from avacopan.
InflaRx N.V. announced on October 22, 2026 that it presented new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology's Kidney Week 2026, held in Denver, Colorado from October 21 to 25. InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system.1
The company said lab and animal data showed izicopan strongly blocked C5aR-driven inflammatory activity and protected kidney tissue, supporting its potential as a therapy for kidney diseases tied to complement activation.1
Izicopan was tested in two hamster models: one involving renal ischemia-reperfusion injury (IRI), used to model acute kidney injury, and the other involving unilateral ureteral obstruction (UUO), used to model progressive kidney damage and scarring. In both models, oral izicopan significantly reduced kidney injury compared with vehicle-treated controls.1
In the IRI model, a single 100 mg/kg oral dose given four hours before surgery significantly lowered plasma creatinine and blood urea nitrogen levels compared with vehicle (p < 0.001 for both).1 Izicopan also significantly improved histopathology scores and reduced infarction and necrotic area scores (p < 0.05 for each).1
In the UUO model, izicopan dosed orally five hours before surgery and then once daily for 14 days significantly cut BUN levels (p < 0.001) and improved histopathology scores (p < 0.05) versus vehicle.1 There was also a nonsignificant trend toward reduced fibrosis markers.1
The company also presented structural modeling data. According to InflaRx, this analysis offers new insight into izicopan's molecular profile, indicating that relative to avacopan it retains structural features needed for strong C5aR1 binding while a trifluoromethyl group lowers its interaction with the liver enzyme CYP3A4/5, a finding the company says points to low risk of time-dependent enzyme inhibition.1
InflaRx said it is planning further development of izicopan in ANCA-associated vasculitis and additional kidney disease indications.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.